Infections caused by methicillin-resistant Staphylococcus aureus (MRSA) are a major concern cause for clinicians, presenting high mortality and morbidity rates compared to infections caused by methicillin-sensitive Staphylococci.2
Storage: -20C
Application: The antibody may be used in various immunochemical techniques including Immunoblotting1 (~76 kDa), ELISA1, Surface Plasmon Resonance (SPR)1 and Flow cytometry1.
Biochem Physiol Actions: Resistance of S. aureus to methicillin and all beta-lactam antibiotics is due to the activity of PBP2a protein (i.e., penicillin binding protein2a) that is located in the cell wall of the resistant strains.3-4 PBP2a is encoded by mecA gene and belongs to a family of penicillin binding proteins (PBPs). PBPs are membrane-bound enzymes that catalyze the transpeptidation reaction necessary for cross-linkage of peptidoglycan chains.5-6 Contrary to all PBPs, PBP2a has low affinity for all ß-lactam antibiotics.7 Therefore, in the presence of ß-lactam antibiotics, while normal PBPs are blocked, the PBP2a is able to continue catalyze the transpeptidation reactions enabling cell wall synthesis.4 PBP2a protein is suggested to be a promising candidate for anti-MRSA vaccine development.8